Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of- opportunity SOLTI TOT-HER3 pre-operative study

Oliveira, M; Falato, C; Cejalvo, JM; Vila, MM; Tolosa, P; Salvador-Bo, FJ; Cruz, J; Arumi, M; Luna, AM; Guerra, JA; Vidal, M; Martínez-Sáez, O; Paré, L; González-Farré, B; Sanfeliu, E; Ciruelos, E; Espinosa-Bravo, M; Pernas, S; Izarzugaza, Y; Esker, S; Fan, PD; Parul, P; Santhanagopal, A; Sellami, D; Villacampa, G; Ferrero-Cafiero, JM; Pascual, T; Prat, A

Prat, A (通讯作者)，Univ Barcelona, Hosp Clin Barcelona, August Pi Sunyer Biomed Res Inst IDIBAPS, Med Oncol Dept,Translat Genom & Targeted Therapies, Villarroel 170,Stair 2-5 Floor, Barcelona 08017, Spain.

ANNALS OF ONCOLOGY, 2023; 34 (8): 670

Abstract

Background: Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody-drug conjugate composed of a fully......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索